IRVINGTON, N.Y., Oct. 16, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed and is commercializing MelaFind®, the first and only FDA approved optical diagnostic device for melanoma detection used by dermatologists in their fight against melanoma, today announced that the company will be participating in the 32nd Annual Fall Clinical Dermatology Conference taking place October 17 – 20, 2013 in Las Vegas, Nevada.
The Fall Clinical Dermatology Conference is a four-day sold-out medical conference that is well attended by over 500 dermatologists, dermatology residents, fellows, physician assistants and nurse practitioners. The conference offers attendees cutting-edge information on the diagnosis and treatment of various conditions related to medical, surgical and cosmetic dermatology.
MELA Sciences will exhibit four poster presentations of clinical data that demonstrate how MelaFind® has assisted dermatologists in making better biopsy decisions and helped them identify early melanomas. The poster data was derived from studies conducted in both clinical and practice settings and reinforces the importance of MelaFind® as an optical imaging device for dermatologists to aid them in the diagnosis of melanoma.
In addition, MELA Sciences will be hosting its first Clinical Advisory Meeting among Key Opinion Leaders (KOLs) at the conference. Mark S. Nestor, MD, PhD, Voluntary Associate Professor of the Department of Dermatology and Cutaneous Surgery at the University Of Miami Leonard Miller School Of Medicine will be moderating the company's Clinical Advisory Meeting during the conference along with Darrell Rigel, MD, MS, Clinical Professor of Dermatology at New York University, Langone Medical Center and MELA Sciences' Chief Medical Advisor to the Board of Directors.
"Melanoma is an ever-growing problem for people of all ages, genders and skin tones, especially those who are high risk, and prevention as well as early detection are essential for survival," said Dr. Nestor. "I find MelaFind® to be a useful tool in my practice especially when dealing with patients with numerous moles with atypical appearance. MelaFind® can help me validate my decision on whether or not to biopsy a marginal lesion, and may, in certain cases allow me to feel comfortable following a lesion clinically instead of performing a biopsy."
According to the Skin Cancer Foundation, melanoma is currently the deadliest and fastest growing cancer in the U.S., with one American dying from melanoma every hour. Skin cancer has reached epidemic proportions, even though the cause (ultraviolet rays) and prevention (sun protection) is known. Melanoma is almost 100% curable if caught early, but according to a Harris Interactive Study commissioned by MELA Sciences only 24 percent of American adults have had a skin check by a dermatologist, which can lead to missed cases as well as potentially advanced and fatal stages.